Loading provider…
Loading provider…
Infectious Disease Physician in San Francisco, CA
NPI: 1346378940Primary Practice Location
ZUCKERBERG SAN FRANCISCO GENERAL HOSP & TRAUMA CTR
1001 Potrero Ave, San Francisco, CA
Primary Employer
Zuckerberg San Francisco General Hospital and Trauma Center
zuckerbergsanfranciscogeneral.org
HQ Phone
Get MD Anne's Phone Numberphone_androidMobile
Get MD Anne's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2001 - 2027

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Infectious Disease
Harvard Medical School
hms.harvard.edu
Medical School
Until 1999
UCSF School of Medicine
medschool.ucsf.edu
Residency • Internal Medicine
1999 - 2002
Fellowship • Infectious Disease
2003 - 2006
Authors: Barbara Haller, Julie Higashi, Dean Schillinger, Lisa Winston, Adithya Cattamanchi
Journal: JAMA Intern Med
Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials
Authors: Parvez Mantry, Robert Brown
Publication Date: 2018-06
Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells.
Authors: Kapil Saharia
Publication Date: 2016-03-10
Lead Sponsor: University of California, San Francisco
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID), University of Washington, Mayne Pharma International Pty Ltd, San Francisco Department of Public Health
Intervention / Treatment: DRUG: Doxycycline Hyclate Delayed-Release 200 mg
Lead Sponsor: University of California, San Francisco
Collaborators: Janssen Scientific Affairs, LLC
Intervention / Treatment: DRUG: Sofosbuvir + Simeprevir
Lead Sponsor: University of California, San Francisco
Collaborators: Bristol-Myers Squibb
Intervention / Treatment: DRUG: continued standard of care with tenofovir in addition to emtricitabine or lamivudine, DRUG: Entecavir with continued standard of care antiretroviral therapy